Form 4: Phibro CEO Sells Shares Under 10b5-1 Plan

Phibro Animal Health Corp's President and CEO, Jack Bendheim, sold 328 shares of Class A Common Stock for approximately $40.09 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported a sale of Class A Common Stock.
• On January 7, 2026, 328 shares of Class A Common Stock were sold.
• The shares were sold at a weighted average price of $40.0877 per share, with prices ranging from $40.035 to $40.26.
• The transaction was executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Following the transaction, Jack Bendheim directly holds 16,840 shares, and BFI Co., LLC indirectly holds 38,872 shares, over which Mr. Bendheim exercises voting and dispositive power.

Sentiment

Score: 5

Explanation: Neutral. The sale is a pre-planned insider transaction under a 10b5-1 plan, which mitigates the negative perception typically associated with insider selling. It's a routine disclosure without significant positive or negative implications for the company's operational performance or strategic direction.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to immediate market conditions.

Negatives

• An insider, who is also the President and CEO and a 10% owner, sold shares of the company's stock.

Risks

• Potential investor perception risk associated with insider selling, even if pre-planned.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged plan, which typically has minimal direct impact on broader industry trends in animal health. It reflects an individual's portfolio management rather than a strategic industry move.

Related Party Transactions

• The transaction involves Jack Bendheim, President and CEO, Director, and 10% owner, and BFI Co., LLC, a 10% owner over which Mr. Bendheim exercises control, making it a related party transaction.

Stakeholder Impact

• Shareholders: May observe a slight increase in available shares on the market, but the impact is minimal due to the small volume and pre-planned nature of the sale. Could lead to minor shifts in investor sentiment regarding insider confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider sale under a 10b5-1 plan by the CEO. The volume of shares sold (328) is relatively small compared to the total beneficial ownership and the company's market capitalization. Such transactions are typically for personal financial planning and do not usually signal a change in the company's fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, 10% Owner